Omeros corporation reports recovery and survival of all patients in study evaluating narsoplimab for treatment of covid-19-associated acute respiratory distress syndrome

Seattle--(business wire)--omeros corporation (nasdaq: omer) today reported the results of a compassionate-use study evaluating narsoplimab, omeros’ investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (masp-2), in the treatment of covid-19 patients with acute respiratory distress syndrome (ards), a severe and life-threatening symptom of covid-19. all patients initially required mechanical ventilation, and all recovered and survived with narsopli
OMER Ratings Summary
OMER Quant Ranking